REFERENCES
- Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360–361.
- Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
- Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30\(suppl 2):S171–176.
- Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV pa-tients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 200128: 124–131.
- Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs. 1999;58:1099–1135.
- Damle BD, Kaul S, Behr D, Knupp C. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacot 2002;42:791–797.
- Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacot 2002;42:419–427.
- Iribarren JA, Labarga P, Rubio R, et al. [Spanish GESIDA/ Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm lnfecc Microbiol Clin. 2004;22: 564–642.
- Damle B, Hess H, Kaul S, Knupp C. Absence of clinically relevant drug interactions following simultaneous adminis-tration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Dispos. 2002;23:59–66.
- Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother. 2002;46:385–391.
- Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:437–443.
- Ruhnke M, Bauer FE, Seifert M, Trautmann M, Hille H, Koeppe P. Effects of standard breakfast on pharmacoki-netics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother. 1993;37:2153–2158.
- Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer FE. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol. 199140: 305–308.
- Nazareno LA, Holazo AA, Limjuco R, et al. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res. 1995;12:1462–1465.
- Ahluwalia G, Cooney DA, Hartman NR, et al. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. Drug Metab Dispos. 1993;21:369–376.
- Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses. 2000;16:415–421.
- la Porte C, Verweij-van Wisen C, van Ewijk N, et al. Phar-macokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunters. J Clin Pharmacol. 2005;45:211–218.
- Reynes J, Denisi R, Massip P, Izopet J, Pellegrin I, Segondy M. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group. J Acquir Immune Defic Syndr. 1999;22:103–105.
- Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther. 2001;6:249–253.